Pharmaceuticals News and Research

RSS

Mylan receives FDA approval for generic Precose Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer's disease and major psychiatric disorders.

18 Jan 2011

ETP introduces online epilepsy diary management tool to advance patient care

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy and seizures and the parent organization of epilepsy.com, today announced that it has expanded the use of its online epilepsy diary management tool with the launch of a new app developed to run on the Android mobile operating system.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

Study: Health advocacy groups don't always disclose drug company funding

The researchers noted that since these lobbying organizations often urge greater access to new drugs and treatments, these contributions should be made public.

14 Jan 2011

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Journal of the National Cancer Institute: Projections Of The Cost Of Cancer Care In The United States: 2010-2020 - "By combining cancer prevalence with average annual costs of cancer care by phase of care and tumor site for 13 cancers in men and 16 cancers in women" and "all cancer sites combined," the authors project there will be just over 18 million cancer survivors in 2020 compared to 13.8 million survivors in 2010.

14 Jan 2011

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer.

14 Jan 2011

Collaborative Drug Discovery receives additional grant for TB drug research

Collaborative Drug Discovery, Inc. (CDD) today announced that the Bill & Melinda Gates Foundation has extended its previous grant to CDD to create a novel database to spark collaborative efforts to discover more effective drugs against tuberculosis (TB). The TB bacillus infects approximately one third of the world's population and the disease kills over 1.5 million people every year.

From Collaborative Drug Discovery, Inc. 14 Jan 2011

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2011 ended November 30, 2010 (1QFY11).

14 Jan 2011

Unintended direct conflict between pharmaceutical marketing and public health

Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients - a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.

14 Jan 2011

ICON announces acquisition of Oxford Outcomes

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy.

14 Jan 2011

Covidien announces support for FDA on safe use of acetaminophen

Covidien, a leading global provider of healthcare products and the world's largest producer of acetaminophen, supports the U.S. Food and Drug Administration (FDA) on the safe use of acetaminophen.

14 Jan 2011

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced commencement of operations on the initial phase of production at the Company's Fengxian facility. This new multi-purpose pharmaceutical development and cGMP manufacturing facility is located in Fengxian in the suburbs of Shanghai, China.

14 Jan 2011

Orexo, Invida enter exclusive licensing and distribution agreement for Abstral in Asia Pacific

Orexo AB and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo's product for the treatment of breakthrough cancer pain.

14 Jan 2011

FDA approves Cumberland's Acetadote Injection

Cumberland Pharmaceuticals today announced that it has received approval from the U.S. Food and Drug Administration for a new formulation of Acetadote Injection, the Company's product used to treat acetaminophen poisoning.

13 Jan 2011

FDA calls for cuts in Acetaminophen in painkillers

The US FDA has asked for a limit on the amount of acetaminophen in prescription pain medicines in an effort to reduce the risk of liver damage. The announcement yesterday asked manufacturers to limit combination drugs such as the opioids Percocet and Vicodin to 325 milligrams of acetaminophen per pill and asked them to carry a “black box” warning about potential liver failure. At present these combinations carry up to 750 milligrams of acetaminophen.

13 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

Over 80% of all pharmaceutical products are in the solid dosage form. Particulate processes therefore abound in the pharmaceutical industry. These include crystallization; drying, granulation, and coating; tablet compaction; fine powder transport, mixing, and blending. These and other particulate processes are used for the large-scale manufacture of tablets and capsules as well as dry powder inhalants for public consumption.

13 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

Pharmaceuticals News and Research

Mylan receives FDA approval for generic Precose Tablets ANDA

Seordus recieves Japanese patent for SER100

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

ETP introduces online epilepsy diary management tool to advance patient care

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Study: Health advocacy groups don't always disclose drug company funding

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Collaborative Drug Discovery receives additional grant for TB drug research

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

Unintended direct conflict between pharmaceutical marketing and public health

ICON announces acquisition of Oxford Outcomes

Covidien announces support for FDA on safe use of acetaminophen

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

Orexo, Invida enter exclusive licensing and distribution agreement for Abstral in Asia Pacific

FDA approves Cumberland's Acetadote Injection

FDA calls for cuts in Acetaminophen in painkillers

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

PPPI-III conference to focus on fundamental research and industrial application of particulate processing

BioCryst reports positive results from peramivir Phase 3 study in influenza

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence